Drug Approval | June 08, 2023
Zydus receives final approval from the USFDA for Tadalafil Tablets USP
Tadalafil Tablets USP, 20 mg had annual sales of USD 61 mn in the United States (IQVIA MAT April 2023)
Tadalafil Tablets USP, 20 mg had annual sales of USD 61 mn in the United States (IQVIA MAT April 2023)
Records revenue growth of 22% to Rs. 762 crores in Q4 FY23 and grew 30% to Rs. 3149 crores in FY23
The successful outcome of this study represents an important milestone in Dr. Reddy's commitment to make highquality biosimilar products more accessible and affordable
The new Biolys provides higher concentration of L-lysine
One thousand times more soluble than L-cystine at neutral pH
US formulations revenue increased by 11.6% YoY to Rs. 3,045 crore and Europe formulation revenue stood at Rs. 1,660 crore
Operating EBITDA increased by 21% to INR 181 crores in Q4 FY23
Lonza launches the TheraPEAK T-VIVO Cell Culture Medium with a novel chemically defined formulation developed to optimize and streamline CAR T-cell manufacturing
The approval paves the way for consolidating the company’s position in Kenya and other African markets as part of its global expansion plans
The USFDA had classified Strides Puducherry facility as OAI in May 2019 followed by issuing a warning letter to this site in July 2019.
Subscribe To Our Newsletter & Stay Updated
